anagrelide

(redirected from Agrelin)

anagrelide

 [an-ag´rĕ-līd]
an agent used in the form of the hydrochloride salt to reduce elevated platelet counts and the risk of thrombosis in treatment of hemorrhagic thrombocythemia; administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

anagrelide

A cytoreductive agent used to manage essential thrombocythaemia and thrombocythaemia due to myeloproliferative disorders (e.g., CML, polycythemia vera) to reduce platelets, risk of thrombosis and other symptoms. It is generally regarded as a second-line therapy compared to hydroxyurea.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

Anagrelide

An orphan drug that is approved for treating PV patients on an investigational basis. Anagrelide works by controlling the level of platelets in the blood.
Mentioned in: Polycythemia Vera
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
The four products in the Phase III bracket are Roberts Pharmaceutical Corp.'s Agrelin, Upjohn Co.'s Freedox sterile solution, Miles Inc.'s nimodipine and Organon Inc.'s orgaran.
Agrelin, an anagrelide, is indicated for preventing strokes in patients with thrombocytosis (which is an overabundance of platelets).
Roberts expects to file a new drug application for Agrelin sometime early this year.